Early Time-Restricted Eating for Cardiovascular Health
ALIGN
Aligning Clocks: Time-Restricted Eating to Improve Cardiovascular Health in Hypertensive Older Adults Who Skip Breakfast
2 other identifiers
interventional
36
1 country
1
Brief Summary
This study will examine whether eating earlier in the day within a consistent 8-hour eating window can improve heart and blood vessel health in older adults with high blood pressure who often skip breakfast. Participants will be randomly assigned to either follow an early time-restricted eating schedule or continue their usual eating habits for 12 weeks. Researchers will measure blood pressure, blood vessel function, and biological markers related to the body's internal clock and oxidative stress to better understand how meal timing affects cardiovascular health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable hypertension
Started Aug 2026
Typical duration for not_applicable hypertension
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 3, 2026
CompletedFirst Posted
Study publicly available on registry
June 9, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2029
Study Completion
Last participant's last visit for all outcomes
August 31, 2029
June 9, 2026
June 1, 2026
2.7 years
June 3, 2026
June 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
24-Hour Systolic Blood Pressure
Change in mean 24-hour systolic blood pressure measured using ambulatory blood pressure monitoring (ABPM). Blood pressure will be recorded over a 24-hour period to assess the effects of early time-restricted eating on blood pressure regulation.
Baseline (Week 0), Week 6, and Week 12 of the intervention
Secondary Outcomes (1)
Flow-Mediated Dilation
Baseline (Week 0), Week 6, and Week 12 of the intervention
Study Arms (2)
Early time-restricted eating (eTRE) group
EXPERIMENTALParticipants in the eTRE group will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-9:30 am), 6 days/week for 12 weeks.
Control group
NO INTERVENTIONParticipants in the control group will be instructed to maintain habitual eating patterns.
Interventions
Participants in the eTRE group will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-9:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.
Eligibility Criteria
You may qualify if:
- Men and women ≥ 60 years old
- Average office systolic BP ≥130 mmHg5
- Self-reported skipping breakfast for at least 3 days in the past 7 days
- Identified as having a morning or evening chronotype according to the Morningness-Eveningness Questionnaire68
- Stable health history over the past 2 months
- Stable medication history over the past 2 months, as recommended by the primary provider
- Willing and able to provide informed consent.
You may not qualify if:
- Fasting \>13 hours per day
- Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake
- Resting heart rate of \>120 beats/minute, systolic BP \>180 and/or diastolic BP \>100 mmHg
- Have lost ≥ 10 pounds in last 3 months
- Self-reported exercise over 90 min/week
- Unable to wake up at a regular time between 6-9 am
- Perform overnight shift work more than 1day/week on average
- Have been diagnosed with diabetes
- On insulin or diabetes medication
- Unstable angina, heart attack or stroke in the past 3 months
- Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure
- Pregnant or breastfeeding
- Rheumatoid arthritis, Parkinson's disease or currently on dialysis
- Current diagnosis of a major psychiatric condition that would impair study participation
- Severe gastrointestinal disease, major gastrointestinal surgery, or active gallstone disease
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alabama at Birmingham
Birmingham, Alabama, 35205, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Instructor
Study Record Dates
First Submitted
June 3, 2026
First Posted
June 9, 2026
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
March 31, 2029
Study Completion (Estimated)
August 31, 2029
Last Updated
June 9, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Starting Date Available: 09/01/2029 Ending Date Available: 08/31/2034
- Access Criteria
- De-identified data will be available to qualified researchers whose proposed use of the data has been approved by the study investigators. Access will be provided for research purposes that are consistent with the informed consent provided by study participants. Researchers may request access by contacting the Principal Investigator and may be required to sign a data use agreement prior to receiving the data. Data will be shared electronically through secure file transfer methods.
De-identified individual participant data underlying the results reported in publications arising from this study will be shared. These data may include demographic characteristics, blood pressure measurements, flow-mediated dilation (FMD) assessments, and anthropometric measurements.